Related Experiment Videos
Increased dosage requirements of gentamicin in burn patients
Abstract:
In 14 burn patients treated for serious Gram-negative infections, the use of the previously recommended gentamicin dose of 5 mg/kg/day was found to result in subtherapeutic serum concentrations (peak concentration less than 4 mg/L). The gentamicin half-life was found to be unusually short especially in the younger burn patients. Because of this shorter half-life the dosage interval was decreased to 4 hours to prevent extended periods of subtherapeutic serum concentrations. In addition, the daily dose of gentamicin was increased to achieve therapeutic peak concentration. Individualizing each patient's gentamicin regimen was thought to be instrumental in the favorable response of two patients with Pseudomonas ecthyma gangrenosum. The results of this study would strongly support the measurement of serum gentamicin levels in all burn patients with life-threatening infection. The gentamicin dosage regimen should then be individualized for each patient to provide optimal peak concentrations. In addition, patients demonstrating a short drug half-life may require a decreased dosage interval to prevent prolonged periods of sub-therapeutic concentrations.
Insights
Standard gentamicin doses are ineffective for burn patients with Gram-negative infections, leading to subtherapeutic levels. Adjusting dosage and frequency is crucial for effective treatment and preventing prolonged low drug concentrations.
Area of Science:
- Pharmacology
- Infectious Diseases
- Burn Medicine
Background:
- Serious Gram-negative infections in burn patients often require aggressive antibiotic therapy.
- Previous gentamicin dosing guidelines may not be effective in this specific patient population.
- Gentamicin is a common antibiotic used for Gram-negative infections.
Purpose of the Study:
- To evaluate the efficacy of standard gentamicin dosing in burn patients.
- To determine optimal gentamicin dosing strategies for burn patients with Gram-negative infections.
- To investigate the pharmacokinetic profile of gentamicin in burn patients.
Main Methods:
- Retrospective analysis of 14 burn patients with serious Gram-negative infections.
- Measurement of serum gentamicin concentrations and half-life.
- Adjustment of gentamicin dosage and frequency based on individual patient data.
Main Results:
- Standard gentamicin dose (5 mg/kg/day) resulted in subtherapeutic serum concentrations (<4 mg/L).
- Shorter gentamicin half-life observed, particularly in younger burn patients.
- Increased daily dose and decreased dosage interval (to 4 hours) achieved therapeutic peak concentrations.
- Individualized gentamicin regimens led to favorable responses in patients with Pseudomonas ecthyma gangrenosum.
Conclusions:
- Standard gentamicin dosing is inadequate for burn patients with Gram-negative infections.
- Therapeutic gentamicin levels require individualized dosing and potentially shorter intervals.
- Monitoring serum gentamicin levels is essential for optimizing treatment in burn patients.
- Shortened gentamicin half-life necessitates dose and interval adjustments to maintain efficacy.